Trial Profile

RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zapnometinib (Primary)
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Proof of concept; Therapeutic Use
Acronyms RESPIRE
Sponsors Atriva Therapeutics

Most Recent Events

04 Oct 2023 According to an Atriva Therapeutics media release, proof-of-concept data from this trial published in the journal eClinicalMedicine (part of THE LANCET Discovery Science).
04 Oct 2023 According to an Atriva Therapeutics media release, the German Federal Ministry of Education and Research funded this trial.
04 Oct 2023 Results presented in an Atriva Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com